The FDA has granted an accelerated approval for Otarmeni (lunsotogene parvec-cwha), the first gene therapy to treat patients ...

A 2026 informational report on Quietum Plus ear ringing relief positioning, auditory nerve support ingredients, proprietary ...

The FDA granted accelerated approval to lunsotogene parvec (Otarmeni) as the first gene therapy for genetic hearing loss, the ...

Supported by the CHORD trial, this AAV vector-based therapy delivers a working copy of the OTOF gene and restores otoferlin protein production.

Elevating the importance of neural health via better diagnosis and treatment is crucial for restoration of natural hearing, ...

The FDA has granted accelerated approval to lunsotogene parvec-cwha (Otarmeni), an adeno-associated virus (AAV) vector–based ...

The treatment, the first of its kind, was approved by the Food and Drug Administration on Thursday. “Our baby was born deaf, ...

The US Food and Drug Administration on Thursday approved the first gene therapy for inherited hearing loss, a one-time ...

Approval in severe-to-profound and profound OTOF -related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of ...

‘I know there will be tears when I cross the finish line’ - Sally Harley ...

Dr. Purodha Prasad, ENT Specialist (Otolaryngologist) in Delhi & founder of Vanya Clinic, Aesthetics & ENT, recently treated ...

A single injection into the inner ear restored functional hearing in 90% of people born deaf because of mutations in the OTOF ...